BACKGROUND: Women with gynecologic cancer are at higher risk of venous thromboembolism (VTE) due to malignancy, pelvic surgery, increased age, and frequently comorbidities. The rate of VTE among different gynecologic cancers and relative to benign gynecologic surgeries has not been reported in a nationally representative cohort. METHODS: Using the American College of Surgeons National Surgical Quality Improvement Program database, gynecologic surgeries were identified retrospectively from 2006 to 2012. Clinical characteristics, surgical procedures, and 30-day postoperative complications were abstracted. Multivariable logistic regression models were performed. RESULTS: Of all gynecologic surgeries (n = 104,368), 11,427 were performed for malignancy: 2.7% (n = 2800) for ovarian cancer, 6.8% (n = 7114) for uterine cancer, 1.0% (n = 1026) for cervical cancer, and 0.5%(n = 487) for vulvar cancer. 202 (1.8%) patients experienced a VTE. Ovarian cancer had a deep venous thrombosis and pulmonary embolism rates of 1.6% and 1.5% compared with uterine cancer, 0.8% and 0.8%, respectively. Ovarian cancer patients were 1.8 (95% confidence interval [CI], 1.19-2.65) times more likely to have a deep venous thrombosis and 1.7 (95% CI, 1.11-2.51) times more likely to have a pulmonary embolism than patients with uterine cancer. Compared with all gynecologic cancer surgeries, ovarian cancer patients were 1.5 times more likely to have a VTE (95% CI, 1.10-2.16). Patients undergoing minimally invasive surgery were 64% less likely to have a VTE regardless of malignancy site; however, if they had disseminated disease, they remained at higher risk of VTE (odds ratio, 5.96; P = 0.027). CONCLUSIONS: Of gynecologic cancer surgeries, ovarian cancer patients had the highest rate of VTE. Venous thromboembolism rates were lower in those who had minimally invasive surgery but remained higher in those with disseminated disease.
BACKGROUND:Women with gynecologic cancer are at higher risk of venous thromboembolism (VTE) due to malignancy, pelvic surgery, increased age, and frequently comorbidities. The rate of VTE among different gynecologic cancers and relative to benign gynecologic surgeries has not been reported in a nationally representative cohort. METHODS: Using the American College of Surgeons National Surgical Quality Improvement Program database, gynecologic surgeries were identified retrospectively from 2006 to 2012. Clinical characteristics, surgical procedures, and 30-day postoperative complications were abstracted. Multivariable logistic regression models were performed. RESULTS: Of all gynecologic surgeries (n = 104,368), 11,427 were performed for malignancy: 2.7% (n = 2800) for ovarian cancer, 6.8% (n = 7114) for uterine cancer, 1.0% (n = 1026) for cervical cancer, and 0.5%(n = 487) for vulvar cancer. 202 (1.8%) patients experienced a VTE. Ovarian cancer had a deep venous thrombosis and pulmonary embolism rates of 1.6% and 1.5% compared with uterine cancer, 0.8% and 0.8%, respectively. Ovarian cancerpatients were 1.8 (95% confidence interval [CI], 1.19-2.65) times more likely to have a deep venous thrombosis and 1.7 (95% CI, 1.11-2.51) times more likely to have a pulmonary embolism than patients with uterine cancer. Compared with all gynecologic cancer surgeries, ovarian cancerpatients were 1.5 times more likely to have a VTE (95% CI, 1.10-2.16). Patients undergoing minimally invasive surgery were 64% less likely to have a VTE regardless of malignancy site; however, if they had disseminated disease, they remained at higher risk of VTE (odds ratio, 5.96; P = 0.027). CONCLUSIONS: Of gynecologic cancer surgeries, ovarian cancerpatients had the highest rate of VTE. Venous thromboembolism rates were lower in those who had minimally invasive surgery but remained higher in those with disseminated disease.
Authors: M S Rasmussen; L N Jorgensen; P Wille-Jørgensen; J D Nielsen; A Horn; A C Mohn; L Sømod; B Olsen Journal: J Thromb Haemost Date: 2006-08-01 Impact factor: 5.824
Authors: N Levitan; A Dowlati; S C Remick; H I Tahsildar; L D Sivinski; R Beyth; A A Rimm Journal: Medicine (Baltimore) Date: 1999-09 Impact factor: 1.889
Authors: Samith Sandadi; Stephen Lee; Adam Walter; Ginger J Gardner; Nadeem R Abu-Rustum; Yukio Sonoda; Carol L Brown; Elizabeth Jewell; Rekha Parameswaran; Richard R Barakat; Mario M Leitao Journal: Obstet Gynecol Date: 2012-11 Impact factor: 7.661
Authors: Nigel S Key; Alok A Khorana; Nigel Mackman; Owen J T McCarty; Gilbert C White; Charles W Francis; Keith R McCrae; Joseph S Palumbo; Gary E Raskob; Andrew T Chan; Anil K Sood Journal: Cancer Res Date: 2016-06-20 Impact factor: 12.701
Authors: William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Katarzyna Bednarska; Ewa Król; Ewa Głowacka; Hanna Romanowicz; Krzysztof Szyłło; Magdalena Klink; Zofia Sułowska; Marek Nowak Journal: Medicine (Baltimore) Date: 2018-03 Impact factor: 1.889
Authors: Saketh R Guntupalli; Alyse Brennecke; Kian Behbakht; Anna Tayebnejad; Christopher A Breed; Lisa Marie Babayan; Georgina Cheng; Amin A Ramzan; Lindsay J Wheeler; Bradley R Corr; Carolyn Lefkowits; Jeanelle Sheeder; Koji Matsuo; Dina Flink Journal: JAMA Netw Open Date: 2020-06-01
Authors: Ruba Sheikh-Ali; January Moore; Tariq Almerey; Beau Toskich; Matthew W Robertson; Tri A Dinh; Houssam Farres Journal: Gynecol Oncol Rep Date: 2019-07-26